Protara Therapeutics (TARA) Long-Term Debt Issuances (2020)

Protara Therapeutics' (TARA) quarterly Long-Term Debt Issuances came in at $1.9 million in Q1 2020.

Protara Therapeutics (TARA) Long-Term Debt Issuances (2020) Analysis & Trends

Protara Therapeutics (TARA) has 1 years of Long-Term Debt Issuances data on file, last reported at $1.9 million in Q1 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $1.9 million in Q1 2020; TTM through Sep 2020 was $1.9 million, a N/A change from a year earlier, with the FY2013 full-year figure at $4.3 million, up 48111.11% from the prior year.
Long-Term Debt Issuances for Q1 2020 stood at $1.9 million.
Over the last five years, Long-Term Debt Issuances for TARA reached as high as $1.9 million in Q1 2020 and fell as low as $1.9 million in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Protara Therapeutics	2.25 Mn	2.25 Mn	-	-

Download Data

Date	Value
Mar 31, 2020	1.87 Mn
Mar 31, 2020	1.87 Mn